ClinicalTrials.gg
CompletedNCT03436394Updated May 16, 2019

Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

A Phase 1 interventional study of Evobrutinib in Renal Impairment, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-16.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
83rd of 113
31 · median 42
Started
2018
with 5 others
Phase 1
54 of 139
1 open now
Registered
87th of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 83rd largest by enrollment of the 113 interventional ones that give a count, is one of 6 that started in 2018, is one of 54 in phase 1, and was the 87th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

The study will investigate the PK and safety of evobrutinib in subjects with different degree of renal impairment as compared to subjects with normal renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Renal Impairment
  • Evobrutinib
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subjects with total body weight between 50.0 and 100.0 kilograms(kg) (inclusive) and (BMI) between 19.0 and 36.0 kg per meter square (inclusive) at the time of the screening examination
  • For subjects with impaired renal function: Subjects must have an according to the Modification of diet in renal disease (MDRD) equation of less than 90 mL per minute at screening and the possibility of stratification to one of the groups and a stable renal function as defined by either: if the time interval between screening and dosing is greater than 10 days, two eGFR with the second estimate within 20% of prior value or historical records of stable function over the past 3 months if within 20 percentage of screening value and within 10 days of dosing
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • History or presence of respiratory, gastrointestinal (including bariatric or other gastric surgeries, or other conditions that may affect drug absorption) hepatic (including hepatorenal syndrome), hematological, lymphatic, neurological (including seizures), cardiovascular (including ventricular dysfunction and congestive heart failure), psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders that may affect the safety of the subject.
  • Clinical history of any disorder
  • Prior history of cholecystectomy or splenectomy, and any surgery within 6 months prior to Screening, which might interfere with the objectives of the study or the study procedures
  • History of any except superficial basal cell carcinoma treated for curative intent may be allowed
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Evobrutinib: Normal Renal Function

    Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) will receive a single oral dose of evobrutinib under fasting conditions.

    Drug: Evobrutinib

  • Experimental
    Evobrutinib: Severe Renal Impairment

    Subjects with eGFR less than (\<) 30 mL/min/1.73 m\^2 will receive a single oral dose of evobrutinib under fasting conditions.

    Drug: Evobrutinib

  • Experimental
    Evobrutinib: Moderate Renal Impairment

    Subjects with eGFR \>= to 30 mL/min/1.73 m\^2 and \< 60 mL/min/1.73 m\^2 will receive a single oral dose of evobrutinib under fasting conditions.

    Drug: Evobrutinib

  • Experimental
    Evobrutinib: Mild Renal Impairment

    Subjects with eGFR \>= to 60 mL/min/1.73 m\^2 and \< 90 mL/min/1.73 m\^2 will receive a single oral dose of evobrutinib under fasting conditions.

    Drug: Evobrutinib

Interventions

  • Subjects will be administered a single oral dose of evobrutinib under fasting conditions.

    Also known as: MSC2364447C, M2951

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  2. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

Secondary outcomes

  1. Occurrences of Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Day 6

  2. Number of Subjects With TEAEs According to Severity

    Time frame: Day 1 up to Day 6

  3. Number of Subjects With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings

    Number of subjects with clinically significant abnormalities will be reported.

    Time frame: Day 1 up to Day 6

  4. Time to Reach the Maximum Plasma Concentration (tmax) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  5. Time Prior to the First Measurable (Non-Zero) Concentration (t lag) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  6. Terminal Rate Constant (λz) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  7. Terminal Half-Life (t1/2) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  8. Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours After Dosing (AUC 0-24h) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  9. Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours After Dosing (AUC 0-8h) of Evobrutinib

    Time frame: Pre-dose up to 8 hours post-dose

  10. Apparent Clearance (CL/f) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  11. Apparent Volume of Distribution During Terminal Phase (Vz/f) of Evobrutinib

    Time frame: Pre-dose up to 30 hours post-dose

  12. Amount of Unchanged Drug (Evobrutinib) Excreted in Urine During Collection Interval (0-8 hours) (Ae0-8h)

    Time frame: Pre-dose up to 8 hours post-dose

  13. Fraction of Administered Drug (Evobrutinib) Excreted in Urine (fe)

    Time frame: Pre-dose up to 30 hours post-dose

  14. Fraction of Unbound Drug (Evobrutinib) in the Plasma (fu)

    Time frame: Pre-dose up to 30 hours post-dose

  15. Renal Clearance of Evobrutinib (CLR)

    Time frame: Pre-dose up to 30 hours post-dose

  16. Non-Renal Clearance of Evobrutinib (CLNonR/f)

    Time frame: Pre-dose up to 30 hours post-dose

07

Study locations

1 site
  • Please Contact the Merck KGaA Communication Center
    Darmstadt, 64293, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Feb 2019, 11 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2018
First posted
Feb 19, 2018
StartActual
Mar 21, 2018
Primary completionActual
Feb 22, 2019
CompletionActual
Feb 22, 2019
Last update
May 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03436394
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Mar 21, 2018
Primary completion
Feb 22, 2019
Completion
Feb 22, 2019
Last update
May 16, 2019

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion